RT Journal Article
SR Electronic
T1 Indomethacin Use for Mild & Moderate hospitalised Covid-19 patients: An open label randomized clinical trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.24.21261007
DO 10.1101/2021.07.24.21261007
A1 Ravichandran, Rajan
A1 Mohan, Surapaneni Krishna
A1 Sukumaran, Suresh Kumar
A1 Kamaraj, Devakumar
A1 Daivasuga, Sumetha Suga
A1 Samuel Ravi, Samson Oliver Abraham
A1 Vijayaraghavalu, Sivakumar
A1 Kumar, Ramarathnam Krishna
YR 2021
UL http://medrxiv.org/content/early/2021/10/03/2021.07.24.21261007.abstract
AB Introduction Indomethacin, a non-steroidal anti-inflammatory drug (NSAID), has been presented as a broad-spectrum antiviral agent. This randomised clinical trial in a hospital setting evaluated the efficacy and safety of this drug in RT-PCR-positive coronavirus disease 2019 (COVID-19) patients.Materials & Methods A total of 210 RT-PCR-positive COVID-19 patients, who provided consent were allotted, to control or case arm, based on block randomisation. The control arm received standard of care comprising paracetamol, ivermectin, and other adjuvant therapies. The patients in the case arm received indomethacin instead of paracetamol, with other medications retained. The primary endpoint was the development of hypoxia/desaturation with SpO2 ≤ 93, while time to become afebrile and time for cough and myalgia resolution were the secondary endpoints.Results The results of 210 patients were available, with 103 and 107 patients in the indomethacin and paracetamol arms, respectively. We monitored patient profiles along with everyday clinical parameters. Blood chemistry at the time of admission and discharge was assessed.As no one in either of the arms required high-flow oxygen, desaturation with SpO2 level of 93 and below was an important goal. In the indomethacin group, none of the 103 patients developed desaturation. On the other hand, 20 of the 107 patients in the paracetamol arm developed desaturation. Patients who received indomethacin also experienced more rapid symptomatic relief than those in the paracetamol arm, with most symptoms disappearing in half the time. 56 patients out of 107 in the paracetamol arm had fever on the seventh day, while no patient in the indomethacin group had fever. Neither arm reported any adverse event. The fourteenth-day follow-up revealed that the paracetamol arm patients had faced several discomforts, including myalgia, joint pain, and tiredness; indomethacin arm patients mostly complained only of tiredness.Conclusion Indomethacin is a safe and effective drug for treating patients with mild and moderate covid-19.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialCTRI Registration No CTRI/2021/05/033544 Funding StatementFunding: Funding for this study was provided by Mr. Kris Gopalakrishnan, Alumnus of the Indian Institute of Technology Madras. He is also the Chairman of Axilor Ventures Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The approval for the study was given by the ethics committee of the Panimalar Medical College. The document no : PMCH&RI/IHEC/2021/051All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available as supplementary file